P58 Biosimilars: enhancing treatment accessibility for patients with psoriasis

Abstract Psoriasis is a systemic inflammatory disease for which biological therapy can be life- transforming. In Chile, access to these treatments is limited by their high cost, which must be covered by patients, as the Chilean health system does not reimburse them. Owing to their lower cost, biosimilars offer an effective alternative to improve access to targeted therapies. Hyrimoz® (an adalimumab biosimilar) was approved by the Chilean Public Health Institute in August 2020 for moderate-to-severe plaque psoriasis. The objective was to describe the characteristics of Chilean patients using Hyrimoz in real life and the treatment response. A multicentre observational study was conducted in four dermatology centres in Santiago. The clinical records of 46 patients with moderate-to-severe psoriasis who did not respond adequately to topical or classic systemic therapies were evaluated between January 2022 and May 2024, for whom Hyrimoz was indicated. Demographic and clinical data were collected. Disease severity was evaluated according to psoriasis area and severity index (PASI) at 0, 3, 6, 9, and 12 months after starting the medication. Efficacy was measured during this period with PASI-75, PASI-90, and PASI-absolute<3. Adverse events reported by the patients and dermatologists were recorded and analysed. Data were analysed using descriptive statistics; 65.2% of patients were men, with an average age of 40.38 ± 12.79 years (16–64 years), and the disease duration was 18.21 ± 9.18 years; 69.6% of patients had comorbidities, the most common being mood disorders and anxiety (12), hypertension (7), and dyslipidaemia (7). All patients received at least one medication prior to the start of Hyrimoz®. The initial PASI was 22.45 ± 10.97 (5.5–52), and the initial body surface area was 23.39 ± 13.13% (3–60%). PASI-75 at 3, 6, 9, and 12 months was 52.38, 88.57, 91.3, and 81.82% respectively. PASI-90 at 3, 6, 9, and 12 months was 40.48, 60, 73.9, and 81.82%. PASI-absolute<3 at 3, 6, 9, and 12 months was 42.85, 68.57, 78.26, and 72.72%. Twenty patients presented with adverse effects: injection site pain (n = 9), infections (n = 8), headache (3); 5 patients of treatment due to loss of efficacy (5/46), and 3 patients for economic reasons (3/46). According to the literature, the observed response in patients was similar to that expected. The introduction of biosimilars in Chile represents an effective alternative that allows economic access to biologics in more patients with moderate–to-severe psoriasis who cannot receive other targeted therapies because of the cost.